Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.

Lee YJ, Moon JH, Shin HC, Seo JW, Han SA, Seo SK, Sohn SK.

Int J Hematol. 2013 Jun;97(6):804-7. doi: 10.1007/s12185-013-1326-8. Epub 2013 Apr 24.

PMID:
23613267
2.

Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.

Turakhia SK, Murugesan G, Cotta CV, Theil KS.

J Clin Pathol. 2016 Aug;69(8):713-9. doi: 10.1136/jclinpath-2015-203498. Epub 2016 Jan 11.

PMID:
26754830
3.
4.

[Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].

Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD.

Ai Zheng. 2004 Dec;23(12):1696-9. Chinese.

PMID:
15601563
5.
6.

A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.

Véronèse L, Tchirkov A, Richard-Pebrel C, Ledoux-Pilon A, Fleury J, Chaleteix C, Goumy C, Gouas L, Berger MG, Vago P, Bay JO, Tournilhac O.

Leuk Res. 2010 Apr;34(4):e94-6. doi: 10.1016/j.leukres.2009.09.025. Epub 2009 Oct 14. No abstract available.

PMID:
19833389
8.

Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia.

Buesche G, Ganser A, Schlegelberger B, von Neuhoff N, Gadzicki D, Hecker H, Bock O, Frye B, Kreipe H.

Leukemia. 2007 Dec;21(12):2420-7. Epub 2007 Sep 6.

PMID:
17805334
9.

Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.

Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.

Clin Cancer Res. 2005 May 1;11(9):3425-32.

10.

A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.

Bee PC, Gan GG, Nadarajan VS, Latiff NA, Menaka N.

Int J Hematol. 2010 Jan;91(1):136-9. doi: 10.1007/s12185-009-0471-6. Epub 2010 Jan 5.

PMID:
20047097
11.

Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?

Qin YZ, Jiang Q, Jiang H, Li JL, Li LD, Zhu HH, Lai YY, Lu XJ, Liu YR, Jiang B, Huang XJ.

Leuk Res. 2013 Sep;37(9):1035-40. doi: 10.1016/j.leukres.2013.06.003. Epub 2013 Jun 26.

PMID:
23810191
12.

[Imatinib therapy for patients with chronic myelogenous leukemia].

Usui N.

Gan To Kagaku Ryoho. 2005 Mar;32(3):297-303. Review. Japanese.

PMID:
15791812
13.

Hematological and molecular response evaluation of CML patients on imatinib.

Gupta A, Prasad K.

J Assoc Physicians India. 2007 Feb;55:109-13.

PMID:
17571739
14.

[Polycythemia vera developed after a major molecular response to imatinib mesylate treatment in a patient with chronic myelogenous leukemia].

Jomen W, Kuroda H, Matsuno T, Sato M, Yamada M, Abe T, Sakurai T, Fujii S, Maeda M, Fujita M, Kato J, Nojiri S.

Rinsho Ketsueki. 2014 Mar;55(3):360-5. Review.

PMID:
24681942
15.

Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.

Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.

Ann Hematol. 2006 Dec;85(12):841-7. Epub 2006 Sep 28.

PMID:
17006667
16.

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.

Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2003 Sep;17(9):1687-94.

PMID:
12970765
17.

Coexistent BCR-ABL1 and JAK2 V617F: converting CML dwarves to ET staghorns with imatinib therapy.

Soderquist C, Bagg A.

Blood. 2014 Oct 9;124(15):2463. No abstract available.

18.

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.

Chu S, Xu H, Shah NP, Snyder DS, Forman SJ, Sawyers CL, Bhatia R.

Blood. 2005 Mar 1;105(5):2093-8. Epub 2004 Sep 2.

19.

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.

Lahaye T, Riehm B, Berger U, Paschka P, Müller MC, Kreil S, Merx K, Schwindel U, Schoch C, Hehlmann R, Hochhaus A.

Cancer. 2005 Apr 15;103(8):1659-69.

20.

Supplemental Content

Support Center